Skip to main content
. 2020 Aug 20;2020:1341863. doi: 10.1155/2020/1341863

Figure 5.

Figure 5

OS of patients in the TACE + RFA group compared with the TACE group in subgroups. (a) OS in AFP < 400 ng/ml group; (b) OS in AFP ≥ 400 ng/ml group; (c) OS in tumor number < 3 groups; (d) OS in tumor number ≥ 3 groups; (e) OS in tumor diameter < 5 cm group; and (f) OS in tumor diameter ≥ 5 cm group.